Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

05 août 2024 08h05 HE | Source: Senti Biosciences, Inc.

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

Senti Bio announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (CIRM).
01 juil. 2024 08h05 HE | Source: Senti Biosciences, Inc.

Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

The California Institute for Regenerative Medicines (CIRM) has awarded an $8 million grant to Senti Bio to support clinical development of SENTI-202.
13 mai 2024 08h15 HE | Source: Senti Biosciences, Inc.

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.
30 avr. 2024 08h05 HE | Source: Senti Biosciences, Inc.

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

Senti Bio today announced the publication of preclinical data that supports the design of the Phase 1 clinical trial of SENTI-202.